Federal Register: FDA Issues Notice, Renewal of Federal Advisory Committee on Pulmonary-Allergy Drugs
May 26, 2026
May 26, 2026
WASHINGTON, May 26 (TNSFR) -- The Food and Drug Administration (FDA) is announcing the renewal of the Pulmonary-Allergy Drugs Advisory Committee by the Commissioner of Food and Drugs. The Commissioner has determined that it is in the public interest to renew the Pulmonary-Allergy Drugs Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the May 30, 2028, expiration date.
SUPPLEMENTARY INFORMATION:
Purs . . .
SUPPLEMENTARY INFORMATION:
Purs . . .